Use of Drugs for ATTRv Amyloidosis in the Real World: How Therapy Is Changing Survival in a Non-Endemic Area

Background: Over the past decade, three new drugs have been approved for the treatment of hereditary amyloid transthyretin (ATTRv) polyneuropathy. The aim of this work was to analyze whether current therapies prolong survival for patients affected by ATTRv amyloidosis. Methods: The study was conduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Russo, Massimo, Gentile, Luca, Di Stefano, Vincenzo, Di Bella, Gianluca, Minutoli, Fabio, Toscano, Antonio, Brighina, Filippo, Vita, Giuseppe, Mazzeo, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146901/
https://www.ncbi.nlm.nih.gov/pubmed/33925301
http://dx.doi.org/10.3390/brainsci11050545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146901/
https://www.ncbi.nlm.nih.gov/pubmed/33925301
http://dx.doi.org/10.3390/brainsci11050545

Ejemplares similares